Table of Contents Table of Contents
Previous Page  47 / 78 Next Page
Information
Show Menu
Previous Page 47 / 78 Next Page
Page Background

45

NCCN Guidelines for Patients

®

Mycosis Fungoides, Version 1.2016

3

DCIS

Genetic counseling | Treatment

4

Treatment guide

Stage IIB treatment

Part 4.3 has two sections based on the extent of the

cancer. The first section,

Limited skin lesions

, typically

includes stage IIB cancers that cover less than 10%

of the skin. The second section,

Widespread skin

lesions

, addresses treatment for stage IIB that covers

10% or more of the skin.

Limited skin lesions

Chart 4.3.1

lists two treatment options for limited

stage IIB cancers. One option is to treat skin tumors

with local radiation therapy. In addition, patches

and plaques may be treated with skin treatments. If

treatment works, you may receive immunotherapy

for a while to prolong the good results. The second

option is to treat the cancer with systemic treatment.

In addition, skin tumors may be treated with

radiation therapy and patches and plaques with skin

treatments. If treatment works, you may stay on

your treatment for a while or slowly stop treatment to

prolong the good results.

Start treatment again if the cancer was fully treated

but came back as stage I, IIA, or limited IIB. People

often have good results with the same treatment. If a

new treatment will be received, the choice of which

treatment will be partly based on how much of your

skin has lesions. If one or two courses of first-line

treatment didn’t work, try another treatment listed in

the chart.

You may have already tried multiple courses of

first-line treatment without much change. Despite

treatment, the cancer may be worse. In either case,

options are listed in Chart 4.3.2.

Chart 4.3.2

lists options for widespread treatment

of stage IIB cancers that were limited in extent at

diagnosis. There are three options. One option is

total skin electron beam therapy. The last two options

include systemic or combination treatments that are

listed in Chart 4.3.3.